Top-News

OKYO PHARMA LTD News

Aktie
WKN:  A2JQ3D ISIN:  GG00BD3FV870 US-Symbol:  EMMLF
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Marktkapitalisierung *
-
Streubesitz
68,08%
KGV
-
Index-Zuordnung
-

OKYO PHARMA LTD News

11.12.25 - GlobeNewswire
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo group These ...
03.12.25 - GlobeNewswire
OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
21.11.25 - GlobeNewswire
OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:  OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
18.11.25 - GlobeNewswire
OKYO Pharma to Present at OIS XV in San Diego
LONDON and NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:  OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
29.10.25 - GlobeNewswire
OKYO Pharma to Present at BIO-Europe 2025 in Vienna
LONDON and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:  OKYO ), a clinical-​stage biopharmaceutical company developing innovative ...
16.10.25 - GlobeNewswire
OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:  OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
22.09.25 - GlobeNewswire
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
17.07.25 - GlobeNewswire
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
LONDON and NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
16.07.25 - GlobeNewswire
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
After 12 weeks of treatment, 75% of per-​protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual ...
11.06.25 - GlobeNewswire
OKYO Pharma to Present at the Bio International Convention
LONDON and NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-​stage biopharmaceutical company developing innovative ...
19.05.25 - GlobeNewswire
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
01.05.25 - GlobeNewswire
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-​focused bio-​pharmaceutical company which is ...
30.04.25 - GlobeNewswire
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-​masked, randomized, 12-week placebo-...
31.03.25 - GlobeNewswire
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term Stability Urcosimod stable in single-​use ampoules for more than 2½ years FDA requires ...
10.03.25 - GlobeNewswire
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
LONDON and NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-​stage biopharmaceutical company developing innovative ...
12.02.25 - GlobeNewswire
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
LONDON and NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
31.01.25 - GlobeNewswire
OKYO Pharma Announces Chairman and CEO Acquire Shares
LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
29.01.25 - GlobeNewswire
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
22.01.25 - GlobeNewswire
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...

Newssuche

Videos

newspaper
12.12.25 +5,47%
Technical Trading: Neues Allzeithoch im Visier
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Anzeige

Aktie im Fokus

Breaking News
ParaZero Technologies Ltd
1,09 €
-2,68%
ParaZero Technologies Ltd Chart
Parazero Technologies und die Bundespolizei!
Mehr zur Aktie »